Insider Selling: Karyopharm Therapeutics major shareholder Sells 8,027 Shares of Stock (KPTI)
Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik unloaded 8,027 shares of Karyopharm Therapeutics stock on the open market in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $39.11, for a total transaction of $313,935.97. The sale was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 2.74% during mid-day trading on Wednesday, hitting $36.50. 89,316 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 52-week low of $15.50 and a 52-week high of $47.98. The stock has a 50-day moving average of $36.98 and a 200-day moving average of $34.43. The company’s market cap is $1.192 billion.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.02) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.52. On average, analysts predict that Karyopharm Therapeutics will post $-2.19 earnings per share for the current fiscal year.
A number of research firms have recently commented on KPTI. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One analyst has rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $52.67.
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.